{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:51:22Z","timestamp":1794012682779,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82225015"],"award-info":[{"award-number":["82225015"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271378"],"award-info":[{"award-number":["82271378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571542"],"award-info":[{"award-number":["82571542"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82488301"],"award-info":[{"award-number":["82488301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3501303"],"award-info":[{"award-number":["2022YFC3501303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3501304"],"award-info":[{"award-number":["2022YFC3501304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021ZD0202400"],"award-info":[{"award-number":["2021ZD0202400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.medj.2026.101026","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:40:53Z","timestamp":1772034053000},"page":"101026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19\/BCMA CAR-T cell therapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Zhe","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naibo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-8017","authenticated-orcid":false,"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101026_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.medj.2026.101026_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","article-title":"Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis","volume":"18","author":"Ruetsch-Chelli","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.medj.2026.101026_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","volume":"144","author":"Rose","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.medj.2026.101026_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0090-1229(85)90018-2","article-title":"Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis","volume":"34","author":"Fujii","year":"1985","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.medj.2026.101026_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1212\/WNL.35.4.577","article-title":"Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis","volume":"35","author":"Fujii","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2026.101026_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1212\/WNL.33.5.604","article-title":"In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood mononuclear cells of patients with myasthenia gravis","volume":"33","author":"Lisak","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2026.101026_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101026_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.medj.2026.101026_bib15","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101026_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib19","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.cell.2024.04.009","article-title":"FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice","volume":"187","author":"Momenilandi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101026_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.280","article-title":"Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing","volume":"11","author":"S\u00e1nchez-Mart\u00ednez","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.medj.2026.101026_bib21","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101026_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/imr.12749","article-title":"Cell circuits and niches controlling B cell development","volume":"289","author":"Zehentmeier","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2026.101026_bib23","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1038\/s41467-020-16828-y","article-title":"An Erg-driven transcriptional program controls B cell lymphopoiesis","volume":"11","author":"Ng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101026_bib24","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1182\/blood-2009-07-230631","article-title":"IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production","volume":"115","author":"Maeda","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101026_bib25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2004-11-4422","article-title":"Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells","volume":"106","author":"Nilsson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101026_bib26","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2026.101026_bib27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2026.101026_bib28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.medj.2026.101026_bib29","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.medj.2026.101026_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2026.101026_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101026_bib32","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2026.101026_bib33","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101026_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.medj.2026.101026_bib35","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41588-023-01528-2","article-title":"Cellular plasticity of the bone marrow niche promotes hematopoietic stem cell regeneration","volume":"55","author":"Hirakawa","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2026.101026_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859668","article-title":"Functional and Immune Modulatory Characteristics of Bone Marrow Mesenchymal Stromal Cells in Patients With Aplastic Anemia: A Systematic Review","volume":"13","author":"Atmar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101026_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-981-32-9717-3_8","article-title":"Stimulatory and Inhibitory Co-signals in Autoimmunity","volume":"1189","author":"Okazaki","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.medj.2026.101026_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12964-023-01289-9","article-title":"Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice","volume":"21","author":"Daei Sorkhabi","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.medj.2026.101026_bib39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/cvr\/cvy308","article-title":"The haematopoietic stem cell niche: a new player in cardiovascular disease?","volume":"115","author":"Al-Sharea","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.medj.2026.101026_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13287-025-04213-9","article-title":"Purine metabolism in bone marrow microenvironment inhibits hematopoietic stem cell differentiation under microgravity","volume":"16","author":"Liu","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.medj.2026.101026_bib41","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101026_bib42","first-page":"100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.medj.2026.101026_bib43","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41596-020-0336-2","article-title":"Scalable SCENIC workflow for single-cell gene regulatory network analysis","volume":"15","author":"Van de Sande","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.medj.2026.101026_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","article-title":"CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics","volume":"20","author":"Jin","year":"2025","journal-title":"Nat Protoc"},{"key":"10.1016\/j.medj.2026.101026_bib45","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-0220","article-title":"Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials","volume":"23","author":"Yan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101026_bib46","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.cell.2022.05.020","article-title":"Bone marrow hematopoiesis drives multiple sclerosis progression","volume":"185","author":"Shi","year":"2022","journal-title":"Cell"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:59:10Z","timestamp":1778921950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666634026000292"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101026","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19\/BCMA CAR-T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101026"}}